112 related articles for article (PubMed ID: 2310202)
21. Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Kuratsu JI; Arita N; Kayama T; Kubo N; Mori T; Sawamura Y; Ushio Y
J Neurooncol; 2000 Jun; 48(2):145-9. PubMed ID: 11083079
[TBL] [Abstract][Full Text] [Related]
22. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
23. [Carminomycin study in breast cancer].
Lichinitser MR; Assekritova IV; Gorbunova VA; Arseriĭ SA; Vaarik KhM
Antibiotiki; 1978 May; 23(5):453-7. PubMed ID: 350145
[TBL] [Abstract][Full Text] [Related]
24. [Phase I and pharmacokinetic study of SM-5887 by 5-day schedule].
Inoue K; Matsumura A; Horikoshi N; Aiba K; Mukaiyama T; Matsumura T; Ogihara A; Sumida T; Ogawa M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):477-82. PubMed ID: 1558397
[TBL] [Abstract][Full Text] [Related]
25. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetics of KRN 8602 in cancer patients].
Majima H; Shinkai H
Gan To Kagaku Ryoho; 1991 Dec; 18(15):2589-95. PubMed ID: 1746971
[TBL] [Abstract][Full Text] [Related]
27. [Phase I trial of 4'-O-tetrahydropyranyl-doxorubicin (THP)--a multi-institutional cooperative study].
Wakui A; Yokoyama M; Konno K; Nakai Y; Sakano T; Koyama Y; Imamura Y; Nakajima O; Niijima T; Akaza H
Gan To Kagaku Ryoho; 1985 Jan; 12(1):118-24. PubMed ID: 3966806
[TBL] [Abstract][Full Text] [Related]
28. [Preliminary phase II clinical study of 4'-O-tetrahydropyranyl doxorubicin (THP-ADM)].
Majima H
Gan To Kagaku Ryoho; 1983 Mar; 10(3):805-10. PubMed ID: 6882000
[TBL] [Abstract][Full Text] [Related]
29. [A phase I study of 4'-epi-adriamycin, a new anthracycline anticancer agent].
Kimura K; Wakui A; Saito T; Tominaga T; Niitani H; Fujimoto T; Masaoka T; Toki H; Tamura K
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2414-9. PubMed ID: 6594078
[TBL] [Abstract][Full Text] [Related]
30. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1997; 40(3):202-8. PubMed ID: 9219502
[TBL] [Abstract][Full Text] [Related]
32. [Phase I study of a new antitumor antibiotic, neothramycin].
Kimura K; Ogawa M; Wakui A; Oguro M; Koyama Y; Saito T; Furue H; Ota K; Yamada K; Hoshino A; Nakamura T; Masaoka T; Taguchi T; Kimura I; Hattori T
Gan To Kagaku Ryoho; 1982 May; 9(5):924-9. PubMed ID: 7184435
[TBL] [Abstract][Full Text] [Related]
33. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
Casper ES; Gralla RJ; Young CW
Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
[TBL] [Abstract][Full Text] [Related]
34. [A phase I trial of idarubicin by oral administration].
Ogawa M; Kimura K; Taguchi T; Wakui A; Hattori M; Shimoyama T; Fujita H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
Bastholt L; Dalmark M
Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
[TBL] [Abstract][Full Text] [Related]
36. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
38. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
39. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
40. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]